NOTV INOTIV INC

Inotiv, Inc. to Participate in Upcoming Investor Conferences

Inotiv, Inc. to Participate in Upcoming Investor Conferences

WEST LAFAYETTE, Ind., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that Robert Leasure Jr., President and Chief Executive Officer, and Beth Taylor, Chief Financial Officer, will participate in multiple upcoming investor conferences throughout November 2023.

Event: Jefferies London Healthcare Conference

Location: London, United Kingdom

Presentation Date: November 15, 2023

Time: 4:00 PM Greenwich Mean Time

Event: 14th Annual Craig-Hallum Alpha Select Conference

Location: New York, NY

Date: November 16, 2023

Event: 6th Annual Evercore ISI HealthCONx Conference

Location: Miami, FL

Presentation Date: November 29, 2023

Time: 3:00 PM Eastern Time





The webcast presentations will be available for viewing and replay under the “Investor Relations” tab of the Company's website at .    

About Inotiv

is a leading contract research organization dedicated to providing nonclinical and analytical drug discovery and development services and research models and related products and services. The Company’s products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development, all while increasing efficiency, improving data, and reducing the cost of taking new drugs to market. Inotiv is committed to supporting discovery and development objectives as well as helping researchers realize the full potential of their critical R&D projects, all while working together to build a healthier and safer world. Further information about Inotiv can be found here: . 

Company ContactInvestor Relations
Inotiv, Inc.LifeSci Advisors
Beth A. Taylor, Chief Financial OfficerBob Yedid
(765) 497-8381(516) 428-8577
  



EN
01/11/2023

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on INOTIV INC

 PRESS RELEASE

Inotiv Provides Notice Regarding Cybersecurity Incident

Inotiv Provides Notice Regarding Cybersecurity Incident WEST LAFAYETTE, Ind., Feb. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, is providing public notice regarding its cybersecurity incident that it became aware of on August 8, 2025. As previously described in the Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on and ...

 PRESS RELEASE

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Pro...

Inotiv Reports First Quarter Financial Results for Fiscal 2026 and Provides Business Update –   First quarter fiscal 2026 revenue increased 0.8% compared to prior year quarter to $120.9 million –   First quarter fiscal 2026 operating loss increased 5.3% compared to prior year quarter to $16.3 million –   Conference call scheduled for today at 8:30 am ET  WEST LAFAYETTE, Ind., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research ...

 PRESS RELEASE

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and...

Inotiv, Inc. to Report Fiscal 2026 First Quarter Financial Results and Host Conference Call on Monday, February 9, 2026 WEST LAFAYETTE, Ind., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2026 first quarter ended December 31, 2025, on Monday, February 9, 2026, before the stock market opens. The Co...

 PRESS RELEASE

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Ap...

Inotiv Leverages LifeNet Health Proprietary Platform to Advance New Approach Methodologies in Translational Drug Discovery WEST LAFAYETTE, Ind., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced a strategic initiative to leverage LifeNet Health’s proprietary TruVivo® within its Discovery and Translational Sciences business. LifeNet Health, a global leader...

 PRESS RELEASE

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bi...

Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities WEST LAFAYETTE, Ind., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization (CRO) specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, and VUGENE, a multi-omics data analysis company providing advanced artificial intelligence (AI) and machine learning (ML) solutions for biomedical research, today announced a strategic collaboration d...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch